Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris Webber

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Expert Review of Vaccines|December 15, 2015
Pneumococcal conjugate vaccine use in adultsRaul E Isturiz, Beate Schmoele-Thoma, Daniel A Scott, et al.
Human Vaccines & Immunotherapeutics|May 14, 2020
Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccineBeatriz Quiambao, Paula Peyrani, Ping Li, et al.
Vaccine|April 15, 2020
Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old childrenTimo Vesikari, Aino Forsten, France Laudat, et al.
Antimicrobial Agents and Chemotherapy|March 27, 2024
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19Lindsay E Clegg, Oleg Stepanov, Henning Schmidt, et al.
Expert Review of Vaccines|November 30, 2017
Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of ageRaul E Isturiz, Cassandra Hall-Murray, John M McLaughlin, et al.
Human Vaccines & Immunotherapeutics|March 16, 2018
Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populationsChristine Juergens, James Trammel, Yasuko Shoji, et al.
Vaccine|April 10, 2019
A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adultsMegumi Inoue, Takuma Yonemura, Richard de Solom, et al.
Molecular Medicine (Cambridge, Mass.)|November 25, 2005
The role of AEBP1 in sex-specific diet-induced obesityLei Zhang, Shannon P Reidy, Tara E Nicholson, et al.
Vaccine|May 13, 2016
Pneumococcal conjugate vaccine herd effects on non-invasive pneumococcal pneumonia in elderlyCornelis H van Werkhoven, Rosalind C Hollingsworth, Susanne M Huijts, et al.
Human Vaccines & Immunotherapeutics|June 30, 2020
Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of AgeTimo Vesikari, Paula Peyrani, Chris Webber, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Expert Review of Vaccines|December 15, 2015
Pneumococcal conjugate vaccine use in adultsRaul E Isturiz, Beate Schmoele-Thoma, Daniel A Scott, et al.
Human Vaccines & Immunotherapeutics|May 14, 2020
Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccineBeatriz Quiambao, Paula Peyrani, Ping Li, et al.
Vaccine|April 15, 2020
Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old childrenTimo Vesikari, Aino Forsten, France Laudat, et al.
Antimicrobial Agents and Chemotherapy|March 27, 2024
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19Lindsay E Clegg, Oleg Stepanov, Henning Schmidt, et al.
Expert Review of Vaccines|November 30, 2017
Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of ageRaul E Isturiz, Cassandra Hall-Murray, John M McLaughlin, et al.
Human Vaccines & Immunotherapeutics|March 16, 2018
Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populationsChristine Juergens, James Trammel, Yasuko Shoji, et al.
Vaccine|April 10, 2019
A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adultsMegumi Inoue, Takuma Yonemura, Richard de Solom, et al.
Molecular Medicine (Cambridge, Mass.)|November 25, 2005
The role of AEBP1 in sex-specific diet-induced obesityLei Zhang, Shannon P Reidy, Tara E Nicholson, et al.
Vaccine|May 13, 2016
Pneumococcal conjugate vaccine herd effects on non-invasive pneumococcal pneumonia in elderlyCornelis H van Werkhoven, Rosalind C Hollingsworth, Susanne M Huijts, et al.
Human Vaccines & Immunotherapeutics|June 30, 2020
Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of AgeTimo Vesikari, Paula Peyrani, Chris Webber, et al.
Pageof 4